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Abstract: Multiple myeloma is the second most common hematological malignancy. Despite all the
progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left
with a median survival of 4–5 years. The combined treatment of multiple myeloma with histone
deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment
option for patients. This study investigated the impact of a combined treatment compared to
treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone
deacetylase (HDAC) inhibitors could reduce cell viability to 59% for KMS 18 cell line and 46% for the
U-266 cell line. The combined treatment led to a decrease of cell viability to 33% for KMS 18 and 27%
for the U-266 cell line, thus showing a significantly better efficacy than the single treatment.
Keywords: multiple myeloma; cytokine-induced killer cells; CIK cells; histone deacetylase inhibitors;
immunotherapy; cancer treatment
1. Introduction
Multiple myeloma (MM) is a hematological malignancy which is characterized by proliferation
and subsequent clonal expansion of atypical plasma cells which produce an excess of monoclonal
immunoglobulin [1,2]. MM cells lead to osteolytic bone destruction by inducing activity of osteoclasts
while suppressing the activity of osteoblasts. Additional to the activation of pre-existing osteoclasts
MM cells stimulate osteoclast neogenesis. On the other hand osteoclasts produce factors promoting
tumor growth. The constant degradation of bone mass leads to lesions in the bone [3]. One of the
reasons MM is so difficult to cure is that MM cells have a close relationship to the bone marrow
micro-environment where the cells receive multiple signals maintaining their longevity and protection
from drug-induced apoptosis [4]. Additionally, MM cells escape the immune system by reducing the
number of natural killer (NK) cell inducing ligands, for example NKG2D, on the surface of the cell
masking them from attacks by NK cells [5].
Cytokine-induced killer (CIK) cells are highly cytotoxic natural killer T (NKT) cells able to lyse
tumor cells. They were shown to proliferate faster than lymphokine activated killer cells and have
a higher cytotoxicity [6,7]. The cytotoxicity is not linked to major histocompatibility complex which
differentiates them from normal cytotoxic T-lymphocytes. The high cytotoxicity derives from the
subgroup of CD3+ and CD56+ co-expressing cells forming a new subset of NKT cells [8]. CIK cells
have already been tested against a variety of different tumor types. Clinical studies showed that CIK
cell treatment is well tolerated by patients and provided better results than conventional therapies.
Additionally some studies suggest that CIK cells counteract viral infections [9].
NKG2D receptors are found on the cell surface of NK cells and NKT cells; they are categorized
as homodimeric C-type lectin-like NK receptors. They bind to various structural homologues of
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MHC-I like MICA or MICB, which are up-regulated in stressed cells and epithelial tumors [10].
Therefore, NKG2D-ligand interactions can mediate anti-tumor and anti-viral immune responses
related to low level signals [11]. After binding to a NK cell activating ligand the NKG2D receptor sends
signals to the NK cell, through tyrosine-based activation molecules, which results in the up-regulation
of their killing ability [12].
Histone deacetylase (HDAC) inhibitors are drugs that can prevent the deacetylation of histones
binding to DNA. HDAC inhibitors bind directly to the site of deacetylation leaving an increased amount
of deacetylated DNA because the active site for HDAC is blocked [13]. Thereby, HDAC inhibitors can
induce cell cycle arrest, re-activate silenced tumor suppressor genes and even induce apoptosis [14].
Furthermore, HDACs also target non-histone proteins such as transcription factors and DNA repair
enzymes, which can be activated by HDAC inhibitors [15]. HDAC inhibitors have already been proven
effective and are used in the treatment of MM improving the outcome. In 2015 the FDA approved
panobinostat which was successfully tested in combination with bortezomib leading to a prolonged
mean survival rate in a placebo study [16]. The aim of this study was to test the combined use of
HDAC inhibitors and CIK cells and to test whether this combination leads to a reduced cell viability of
MM cells. The basis of this study is the observation that both HDAC inhibitors and CIK cells, on their
own, lower the cell viability of tumor cells [17], however, have not been studied in combination yet.
2. Results
In first experiments, it was tested to what extend HDAC inhibitors kill CIK cells. In the next
step, the most potent ratio of CIK to tumor cells was determined. The last step was testing the HDAC
inhibitors Sodium Butyrate (SB), Valproic Acid (VPA) and Trichostatin A (TSA) in combination with
CIK cells on the tumor cell lines, KMS-18 and U-266.
2.1. The Effect of HDAC Inhibitors on Cell Viability of CIK Cells
Figure 1a shows the cell viability of CIK cells in the presence of SB. Cell viability was calculated
in comparison to the cell viability of the untreated CIK control. The viability decreases when the CIK
cells are incubated with Sodium Butyrate.
Figure 1b shows the results for the HDAC inhibitor VPA. When incubated with VPA cell
viability decreases.
Figure 1c shows the cell viability of CIK cells after incubation with TSA. Incubation with the
HDAC inhibitor TSA leads to a significant decrease in cell viability.
(a) (b)
Figure 1. Cont.
Int. J. Mol. Sci. 2017, 18, 945 3 of 9
(c)
Figure 1. Effect of histone deacetylase (HDAC) inhibitors on cytokine-induced killer (CIK) cells.
(a) Effect of Sodium Butyrate (SB) on CIK cells. CIK cells were incubated with H2O, 1, 2, 4, 8 mM
SB for 24 h. The experiment was performed 6 times; (b) Effect of Valproic Acid (VPA) on CIK cells.
CIK cells were incubated with H2O, 0.1, 0.5, 1, 5 mM VPA for 24 h. The experiment was performed
6 times; (c) Effect of Trichostatin A (TSA) on CIK cells. CIK cells were incubated with DMSO, 1, 10, 100,
1000 nM TSA for 24 h. The experiment was performed 6 times.
2.2. Finding the Optimum Ratio of CIK Cells to Tumor Cells
After it was verified that CIK cells survive being exposed to the HDAC inhibitors, it had to be
determined in which ratio the CIK cells should be co-cultured with the tumor cells in order to obtain
the lowest possible cell viability. The results are shown in Figure 2. For KMS 18 cell line, the lowest
cell viability was achieved with a ratio of 1:1. Ratios of 1:5, 1:10, 1:20 and 1:50 resulted in higher
cell viabilities.
Figure 2. Effect of different ratios of CIK cells on both multiple myeloma cell lines. Tumor cells were
incubated with ratios of 1:1, 1:5, 1:10, 1:20 and 1:50 tumor cells to CIK cells for 24 h. The experiment
was performed 6 times for the tumor only and 1:1 ratio of KMS 18 and 9 times for the other KMS 18
related ratios. For the U-266 cell line the experiment was performed 3 times for each ratio.
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Looking at the U-266 cell line, the 1:1 ratio proved to be the most potent ratio. Therefore,
all following experiments were performed with a 1:1 ratio of CIK to MM cells.
2.3. Effect of HDAC Inhibitors and CIK Cells on KMS 18 cells
Finally, tumor cells were incubated with HDAC inhibitors and CIK cells. Figure 3a shows the cell
viability of KMS 18 cells in combination with SB in the presence and absence of CIK cells. The results
show a clear negative trend in cell viability when cells were incubated with SB and even more with the
combination of SB and CIK cells. The difference between the incubation with only the HDAC inhibitor
and the HDAC inhibitor in combination with CIK cells was significant (* p = 0.0152).
(a) (b)
(c)
Figure 3. Effect of HDAC inhibitors on KMS 18 cell line with and without CIK cells. (a) Effect of SB on
KMS 18 cells with and without CIK cells. The KMS 18 cells were incubated with 1, 2, 4, 8 mM SB for 24 h.
Afterwards, CIK cells or new medium was added to the respective wells and incubated for another
24 h. The experiment was performed 9 times; (b) Effect of VPA on KMS 18 cells with and without CIK
cells. The KMS 18 cells were incubated with 0.1, 0.5, 1, 5 mM VPA for 24 h. Afterwards, CIK cells or
new medium was added to the respective wells and incubated for another 24 h. The experiment was
performed 9 times; (c) Effect of TSA on KMS 18 cells with and without CIK cells. The KMS 18 cells were
incubated with 1, 10, 100, 1000 nM TSA for 24 h. Afterwards, CIK cells or new medium was added to
the respective wells and incubated for another 24 h. The experiment was performed 9 times.
Figure 3b shows a similar negative trend of cell viability for the incubation with VPA. The cell
viability decreases with increasing dosage of VPA and again there was a significantly (* p = 0.0152)
higher decrease of cell viability when MM cells were incubated together with VPA and CIK cells.
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Figure 3c shows the cell viability of KMS 18 when incubated with TSA. The negative trend of cell
viability was also present for the HDAC inhibitor TSA. A significantly (** p = 0.0043) bigger decrease
could be observed when the combined treatment of HDAC inhibitor and CIK cells was used.
2.4. Effect of HDAC Inhibitors and CIK Cells on U-266 Cells
Analogous experiments were performed with the U-266 cell line. The results of the SB treatment
are visualized in Figure 4a. As previously seen for the KMS 18 cell line, there is a negative trend
in cell viability of U-266 cells when incubated with SB. The decrease of cell viability is significantly




Figure 4. Effect of HDAC inhibitors on U-266 cell line with and without CIK cells. (a) Effect of SB
on U-266 cells with and without CIK cells. U-266 cells were incubated with 1, 2, 4, 8 mM SB for 24 h.
Afterwards, CIK cells or new medium was added to the respective wells and incubated for another 24 h.
The experiment was performed 9 times; (b) Effect of VPA on U-266 cells with and without CIK cells.
U-266 cells were incubated with 0.1, 0.5, 1, 5 mM VPA for 24 h. Afterwards, CIK cells or new medium
was added to the respective wells and incubated for another 24 h. The experiment was performed
9 times; (c) Effect of TSA on U-266 cells with and without CIK cells. U-266 cells were incubated with 1,
10, 100, 1000 nM TSA for 24 h. Afterwards, CIK cells or new medium was added to the respective wells
and incubated for another 24 h. The experiment was performed 9 times.
Figure 4b shows cell viability of U-266 cells after the treatment with VPA. Similar to the treatment
with HDAC inhibitor SB the treatment with VPA showed a decrease of cell viability. And again the
decrease of cell viability is significantly (** p = 0.0022) higher if HDAC inhibitor and CIK cells were
used in combination. Towards the higher concentrations of VPA cell viability decreases more strongly.
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Figure 4c shows the results after treatment of U-266 cell with TSA. Since TSA was dissolved in
DMSO the initial cell viability was lower than for the previous HDAC inhibitors. Again, an increase of
concentration of HDAC inhibitor led to decreased cell viability. The combination of TSA and CIK cells
led to a significantly (* p = 0.026) higher decrease in cell viability.
3. Discussion
Tumor cells have shown an up-regulation of NK-cell activating ligands after treatment with some
HDAC inhibitors [18]. Here HDAC inhibitors were tested hoping that an up-regulation of NK-cell
activating ligands would lead to an increased recognition and subsequent lysis of MM cells. This was
done in vitro with two multiple myeloma cell lines, KMS 18 and U-266. The experiment showed that
a combination of CIK cells and HDAC inhibitors significantly reduce cell viability of MM cells in vitro.
Additionally, we saw that CIK cells survive exposure to HDAC inhibitors and therefore can be used
in a combined treatment of MM. However, no flow cytometry was performed, therefore it was not
possible to determine if up-regulation of NK-cell activating ligands took place.
CIK cells have already been proven to be effective in the treatment of various tumors and were
found to be very effective in increasing the quality of life in cancer patients as well as in improving
the immune system especially in patients suffering from late stage malignant tumors [19]. CIK cells
have also been proven to be effective in other combinatory treatments for example when used in the
treatment of patients receiving chemotherapy. Here the treatment was found to prolong the survival of
patients. It also enhanced the immune functions of the patients and eased the complications originating
from chemotherapy [20]. Since CIK cells are derived from the patients blood they are well tolerated
by the patient. The combinatory treatment of MM by HDAC inhibitors and CIK cells may constitute
a new treatment method in the future based on the increased recognition of MM cells by CIK cells and
to an improved immune function.
For SB it has been established by flow cytometry that it leads to an up-regulation of MICA [21],
whereas for the other two HDAC inhibitors such studies have yet to be conducted. In the recent past
many NK cell activating substances relying on surface ligands have been approved for treatment of
tumors. AFM13 is a bi-specific antibody that has been reported to lead to a significant increase in NK
cell activation [22]. Elotuzumab is a monoclonal antibody specifically designed to target SLAMF7
in MM. It showed a high efficacy when combined with proteasome inhibitors like bortezomib [23].
Another human monoclonal antibody targeting MM cell surface proteins is Daratumumab targeting
CD38 which is over-expressed on MM cells. Daratumumab was found to be well tolerated by patients
and led to cell death of MM cells via several mechanisms [24]. A study combining Daratumumab
with proteasome inhibitors and dexamethasone showed promising results for patients suffering from
relapsed and refractory MM leading to a significantly prolonged progression-free survival [25]. If all
three HDAC inhibitors up-regulate NK-cell activating ligands a combination of CIK cells HDAC
inhibitors and monoclonal antibodies might result in stronger antibody labeling and an even greater
cytotoxic activity of the CIK cells and NK-cells and lead to prolonged survival rate of patients.
4. Materials and Methods
4.1. Cells
KMS 18 (University of Leeds, Leeds, England) and U-266 (DSMZ, Braunschweig, Germany)
are both cell lines derived from patients suffering from multiple myeloma. Both cell lines were
cultured in 75 cm2 culture flasks using RPMI-medium (PAN Biotech, Aidenbach, Germany)
supplemented with 10% fetal calf serum (FCS) (Gibco Life Technologies, Darmstadt, Germany) and
1% penicillin/streptomycin (P/S) (Life Technologies, Darmstadt, Germany). Cells were kept at 37 °C
and 5% CO2. New Medium was added every 3 days and completely replaced at least once a week or
whenever deemed necessary. Cells were split weekly or whenever splitting was required.
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CIK cells were cultured in RPMI-medium supplemented with 10% FCS and 1% P/S. Additionally the
medium was buffered with 2.5% HEPES buffer (PAN Biotech). Every 3 days part of the medium was
renewed and 300 U·mL−1 interleukin-2 (IL-2) (Immuno Tools, Friesoythe, Germany, and, Novartis Pharma
GMBH, Nuernberg, Germany) was added to the culture flask. CIK cells were not centrifuged, unless part
of the culture was harvested for further experiments.
4.2. Buffy Coat
In a sterile glass container phosphate buffered saline (PBS) and 1% bovine serum albumin (BSA)
(Life Technologies; PAA, Coelbe, Germany) were mixed with 50 mL of blood. Afterwards, a Falcon
tube containing 15 mL Pancoll (PAN Biotech) was carefully overlaid with the blood PBS/BSA mixture.
The tube was centrifuged at 1000 rpm for 30 min while the centrifuge break was switched off and the
centrifuge was allowed to slowly come to a stop.
After centrifugation the whitish middle layer containing the lymphocytes was carefully taken off
with a pipette and transferred into a new falcon tube. The tube was filled to 50 mL and centrifuged
for 7 min at 800 rpm for this the break on the centrifuged was switched back on. Lymphocytes were
washed three times with 50 mL PBS. After the first washing step re-suspension of the pellet was done
in 10 mL erylyse buffer and the tube was incubated on ice for 10 min. In the second washing step
a small amount of resuspended cells was taken for counting in a hemocytometer.
After washing the cell number was adjusted to to 5×106 mL−1 and the cell suspension was split
up so that there was a maximum of 30 mL in one incubation flask. The flask(s) were incubated at 37 °C
and 5% CO2 in order to allow the dendritic cells to settle on the ground and attach to the bottom of
the flask. Afterwards, the medium containing the peripheral lymphocytes was transferred to a new
flask which was filled up to 40 mL with CIK cell medium. In the end 1000 U·mL−1 interferon gamma
(IFN-γ) were added to the cell.
The next day the cells once had to be supplied with:
• 300 U·mL−1 IL-2
• 50 ng·mL−1 α-CD3
• 100 U·mL−1 interleukin1 β (IL-1 β)
Additionally, CIK cells have to be supplemented with 300 U·mL−1 IL-2 every three days.
4.3. MTT Assay
In order to measure and compare the cytotoxicity of the CIK cells a 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assay was performed. The MTT assay was done using 96 well
plates. In each well 1×104 MM cells were plated out with 50 µL of medium and one HDAC inhibitor.
















96-well plates were incubated for 24 h. After incubation 50 µL of CIK cells were pipetted into
the wells. For control 50 µL pure medium was added. On the last day 80 µL medium was pipetted
out of the wells, after centrifugation of the plate, and 55 µL of MTT reagent was added into the wells.
The plates were incubated for 45 min. After a second centrifugation 55 µL were removed from the
wells and 80 µL DMSO was pipetted in the wells. Then the plates were put on a shaker at 37 °C
and 350 rpm for 10 min after which the absorbance of each well was measured and documented in
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a spectrophotometer at 560 nm. In this case, a Glomax Multi Detection System (Promega, Madison,
WI, USA) was used.
Cell viability was calculated from the values gathered with the photometer.
4.4. Statistical Analysis
Statistical analysis was performed using the program Graph Pad Prism 5 (Graph Pad Software
Inc., La Jolla, CA, USA). Data were presented as mean with standard deviation. In order to determine
statistical significance Student’s t-test was used. The statistical significance limit was set to p < 0.05
(ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001).
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